title: Liposomal amphotericin B (AmBisome) compared with amphotericin B +/- FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor/dexamethasone-mobilized allogeneic donor neutrophils.
abstract: Concomitant use of allogeneic donor granulocyte transfusions and amphotericin B in febrile neutropenic recipients may be limited by the increased incidence of respiratory distress. In vitro effects of amphotericin B and AmBisome were compared on polymorphonuclear leukocyte (PMN) aggregation from PMNs isolated from granulocyte-colony-stimulating factor (G-CSF)/dexamethasone-mobilized allogeneic donors. Six allogeneic donors were mobilized with G-CSF (600 microg subcutaneously) and dexamethasone (8 mg orally) 12 hours before leukopheresis. AmBisome was associated with significantly less PMN aggregation (100 microM [microg/mL]) (0.33% +/- 0.33% vs 54.33% +/- 5.82%; P <.001) than amphotericin B. Furthermore, with the addition of the PMN agonist, FMLP, AmBisome was also associated with significantly less aggregation (100 microM [microg/mL]) (18.67% +/- 1.45% vs 54.67% +/- 2.4%; P <.001). In summary, these studies demonstrate that liposomal amphotericin is associated with significantly less in vitro PMN aggregation than amphotericin B and could possibly be administered concomitantly with mobilized allogeneic PMN infusions.
authors.affiliation: Department of Pediatrics, Children's Hospital of New York, Columbia University, New York, NY 10032, USA.
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Sulis
authors.forename: Carmella
authors.initials: C
authors.lastname: Van de Ven
authors.forename: Theresa
authors.initials: T
authors.lastname: Henderson
authors.forename: Lauren
authors.initials: L
authors.lastname: Anderson
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001782:Blood Donors; D002449:Cell Aggregation / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D007937:Leukapheresis; D017708:Leukocyte Transfusion; D008081:Liposomes / Q000008:administration & dosage; D009181:Mycoses / Q000209:etiology / Q000628:therapy; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000008:administration & dosage* / Q000009:adverse effects; D009503:Neutropenia / Q000150:complications / Q000628:therapy; D009504:Neutrophils / Q000187:drug effects*
chemical_list: D000935:Antifungal Agents; D005938:Glucocorticoids; D008081:Liposomes; D016179:Granulocyte Colony-Stimulating Factor; D009240:N-Formylmethionine Leucyl-Phenylalanine; D003907:Dexamethasone; D000666:Amphotericin B